The FDA has approved bemotrizinol, a long-used ingredient in Europe, as a safe and effective sunscreen filter for Americans. This breakthrough promises stronger, longer-lasting UV protection in lighter, less irritating formulations.
- Bemotrizinol shields against UVA and UVB rays with low skin absorption.
- New sunscreens will be lighter, more photostable, and less likely to cause irritation.
- First products with bemotrizinol expected by the end of 2026 in the US.
What happened
Bemotrizinol protects against a broad spectrum of ultraviolet rays, including both UVA and UVB, which are responsible for skin damage and cancer risks. It is also photostable, meaning it does not break down under sunlight and maintains its protective qualities for longer periods. The FDA now allows bemotrizinol to be used up to 6% concentration in over-the-counter sunscreens, expected to hit US store shelves by late 2026 under names like PARSOL Shield.
Why it feels good
By improving broad-spectrum UV protection and durability under sunlight, these next-generation products could significantly decrease the incidence of skin cancers linked to UV exposure. The innovation also demonstrates progress in regulatory science, with faster review times allowing Americans timely access to safer, advanced skincare solutions.
What to enjoy or watch next
Consumers should look forward to new sunscreen brands launching with bemotrizinol later this year, offering better protection in lightweight formulas that feel comfortable on the skin. Those with sensitive skin or children may find these new options particularly appealing as they aim to reduce irritation and improve compliance with sun-safe habits.
Keep an eye on ongoing developments in sunscreen technology as regulatory agencies around the world continue updating ingredients to improve safety and effectiveness. This milestone may also lead to new research and innovations targeting skin cancer prevention, a persistent health challenge in the US and globally.